| abstract |
The invention relates to solid forms of antibodies against the EGF receptor, especially precipitates and crystals of monoclonal antibodies against the EGF receptor, especially preferably Mab C225 (Cetuximab) and Mab h425 (EMD 72000), that create biologically active antibody proteins by dissolution or suspension in an aqueous medium. Said proteins can be obtained by precipitation of the antibody dissolved or suspended in the aqueous medium and/or one of the variants or fragments thereof by means of a precipitation reagent. The invention also relates to pharmaceutical preparations containing at least one solid form of the cited antibody in a precipitated non-crystalline form, a precipitated crystalline form or a soluble or suspended form, and optionally carrier and/or auxiliary substances and/or other pharmaceutical active ingredients, and to a method for producing inventive solid forms of anti-EGFR-antibodies. |